恶性疟原虫磺胺多辛-乙胺嘧啶耐药对非洲妊娠期疟疾间歇性预防治疗效果的影响:系统综述与荟萃分析
该系统综述与荟萃分析纳入57项研究(59 457例出生),评估磺胺多辛-乙胺嘧啶耐药分子标志与IPTp效果的关系。低出生体重相对风险降低在dhps Lys540Glu高耐药地区降至7%,中耐药地区21%,低耐药地区27%;六重突变虫株常见地区IPTp效果甚微。
要点
- IPTp对低出生体重的效果随dhps Lys540Glu耐药率升高而下降。
- 高耐药区RRR仅7%,低耐药区27%,总体RRR为21%。
- 六重突变虫株(含Ala581Gly)常见地区IPTp效果极低。
核心结论
- 在磺胺多辛-乙胺嘧啶高耐药地区,IPTp效果降低,但若六重突变虫株不常见,仍与低出生体重减少相关。
研究设计与样本
- 系统综述与荟萃分析,检索1990年1月1日至2018年3月1日数据库,纳入57项研究(59 457例出生)进行聚合数据荟萃分析。
主要发现
- 低出生体重RRR随dhps Lys540Glu患病率升高而下降(ptrend=0·0060),与Ala437Gly无关(ptrend=0·35)。
- 高耐药区RRR为7%(95%CI 0–13),中耐药区21%(14–29),低耐药区27%(21–33),总体21%(17–25)。
- 个体参与者数据(13项调查,42 394例出生)中,Lys540Glu>90%且Ala581Gly<10%地区RRR为10%(7–12)。
- Ala581Gly≥10%地区(汇总患病率37%,范围29–46%)RRR为0·5%(-16–14)。
临床怎么用
- 在六重突变虫株患病率超过37%的地区,需要磺胺多辛-乙胺嘧啶IPTp的治疗替代方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine threatens the antimalarial effectiveness of intermittent preventive treatment during pregnancy (IPTp) in sub-Saharan Africa. We aimed to assess the associations between markers of sulfadoxine-pyrimethamine resistance in P falciparum and the effectiveness of sulfadoxine-pyrimethamine IPTp for malaria-associated outcomes. METHODS: For this systematic review and meta-analysis, we searched databases (from Jan 1, 1990 to March 1, 2018) for clinical studies (aggregated data) or surveys (individual participant data) that reported data on low birthweight (primary outcome) and malaria by sulfadoxine-pyrimethamine IPTp dose, and for studies that reported on molecular markers of sulfadoxine-pyrimethamine resistance. Studies that involved only HIV-infected women or combined interventions were excluded. We did a random-effects meta-analysis (clinical studies) or multivariate log-binomial regression (surveys) to obtain summarised dose-response data (relative risk reduction [RRR]) and multivariate meta-regression to explore the modifying effects of sulfadoxine-pyrimethamine resistance (as indicated by Ala437Gly, Lys540Glu, and Ala581Gly substitutions in the dhps gene). This study is registered with PROSPERO, number 42016035540. FINDINGS: Of 1097 records screened, 57 studies were included in the aggregated-data meta-analysis (including 59 457 births). The RRR for low birthweight declined with increasing prevalence of dhps Lys540Glu (ptrend=0·0060) but not Ala437Gly (ptrend=0·35). The RRR was 7% (95% CI 0 to 13) in areas of high resistance to sulfadoxine-pyrimethamine (Lys540Glu ≥90% in east and southern Africa; n=11), 21% (14 to 29) in moderate-resistance areas (Ala437Gly ≥90% [central and west Africa], or Lys540Glu ≥30% to <90% [east and southern Africa]; n=16), and 27% (21 to 33) in low-resistance areas (Ala437Gly <90% [central and west Africa], or Lys540Glu <30% [east and southern Africa]; n=30; ptrend=0·0054 [univariate], I2=69·5%). The overall RRR in all resistance strata was 21% (17 to 25). In the analysis of individual participant data from 13 surveys (42 394 births), sulfadoxine-pyrimethamine IPTp was associated with reduced prevalence of low birthweight in areas with a Lys540Glu prevalence of more than 90% and Ala581Gly prevalence of less than 10% (RRR 10% [7 to 12]), but not in those with an Ala581Gly prevalence of 10% or higher (pooled Ala581Gly prevalence 37% [range 29 to 46]; RRR 0·5% [-16 to 14]; 2326 births). INTERPRETATION: The effectiveness of sulfadoxine-pyrimethamine IPTp is reduced in areas with high resistance to sulfadoxine-pyrimethamine among P falciparum parasites, but remains associated with reductions in low birthweight even in areas where dhps Lys540Glu prevalence exceeds 90% but where the sextuple-mutant parasite (harbouring the additional dhps Ala581Gly mutation) is uncommon. Therapeutic alternatives to sulfadoxine-pyrimethamine IPTp are needed in areas where the prevalence of the sextuple-mutant parasite exceeds 37%. FUNDING: US Centers for Disease Control and Prevention, the Malaria in Pregnancy Consortium (funded through a grant from the Bill & Melinda Gates Foundation to the Liverpool School of Tropical Medicine), Worldwide Antimalarial Resistance Network, European and Developing Countries Clinical Trials Partnership.
引用
- van Eijk AM, Larsen DA, Kayentao K, et al. Effect of Plasmodium falciparum sulfadoxine-pyrimethamine resistance on the effectiveness of intermittent preventive therapy for malaria in pregnancy in Africa: a systematic review and meta-analysis. Lancet Infect Dis. 2019. PMID: 30922818. doi:10.1016/S1473-3099(18)30732-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。